MedTrace Logo

SPIRIT V: Post-marketing Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System in Europe

NCT00402272 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2700

Last updated 2010-10-14

No results posted yet for this study

Summary

The purpose of this Clinical Evaluation is a continuation in the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of patients with de novo coronary artery lesions.

Conditions

Interventions

DEVICE

XIENCE V® Everolimus Eluting Coronary Stent

Drug eluting stent implantation stent in the treatment of coronary artery disease.

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Eberhard Grube, MD · The Heart Center, Siegburg, Germany

  • Upendra Kaul, MD · Fortis Hospital, New Delhi, India

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-02-29
Completion
2010-06-30

Countries

  • Austria
  • Belgium
  • Canada
  • China
  • Czechia
  • France
  • Germany
  • Greece
  • India
  • Ireland
  • Israel
  • Italy
  • Malaysia
  • Netherlands
  • New Zealand
  • Portugal
  • Singapore
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00402272 on ClinicalTrials.gov